NEWS ROOM

BIND Biosciences, Inc. selected as 2008 Nano 50 awardee by Nanotech Briefs

07/15/2008

CAMBRIDGE, MA – July 15, 2008 – BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing an entirely new class of targeted therapeutics based on multifunctional nanoparticles, announced today their selection as a 2008 Nano 50 awardee by Nanotech Briefs, a newsletter by the publishers of NASA Tech Briefs. The Nano 50 awards recognize the top 50 technologies, products and innovators that have significantly impacted, or are expected to impact, the state of the art in nanotechnology.  BIND was selected as an awardee in the “Technologies” category, for technology breakthroughs that are expected to have significant and widespread impact.  BIND’s selection as a 2008 awardee in the “Technologies” category follows on a 2007 award in the “Innovators” category to Omid C. Farokhzad, M.D., Scientific Co-founder of BIND and Assistant Professor of Anesthesia at Harvard Medical School.  A complete list of “Nano 50” 2008 award winners is available online at www.nanotechbriefs.com/nano50_winners.html.

About BIND Biosciences, Inc.
BIND Biosciences is a biopharmaceutical company focused on developing “smart” therapeutic targeted nanoparticles capable of differential delivery and controlled drug release to diseased tissue.  The company’s technology enables highly selective targeting at the cellular level and is capable of delivering bioactive agents ranging from approved drugs to emerging drug modalities.  The company’s product platform is broadly applicable across the therapeutic areas of oncology, inflammatory disease, cardiovascular disease and infectious disease.  Their initial product development efforts are focused on cancer and cardiovascular disease with their first product anticipated to enter the clinic in 2009.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Assistant Professor.  The company licensed a large patent estate on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital – Harvard Medical School covering the scientific founders’ work in targeted nanoparticle therapeutics.  The company has assembled a world-class management and scientific team drawn from companies such as Millennium Pharmaceuticals, Alkermes, Infinity Pharmaceuticals, Momenta, Acceleron Pharma, Boehringer Ingelheim Pharmaceuticals and Sepracor. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Ventures and NanoDimension.  For more information, please visit the company’s web site at www.bindbio.com.

Contacts
BIND Biosciences, Inc.
Glenn Batchelder, President and CEO
617-491-3400